Sentence examples for drug development failure from inspiring English sources

In drug development, failure was heartbreaking.

Drug-induced arrhythmia is one of the most common causes of drug development failure and withdrawal from market.

With the cost of conducting clinical trials increasing with each stage in drug development, failure at late stages of development is problematic.

The underlying complexity of multitarget inhibitors makes the development of these drugs challenging, especially when translating from mice to humans. 2 For this purpose, many compounds that showed excellent antitumor properties in animals did not perform as well in patients, which resulted in drug development failure.

The need for detailed mapping of signaling systems is also supported by the fact that several drug development failures were caused by undiscovered cross-talk or regulatory effects of drug targets.

At the same time, it has suffered several setbacks in drug development, including failure of an experimental drug for depression that it was developing with Targacept, an American biotechnology company, and another drug for ovarian cancer.

Anticancer drug development has a high failure or attrition rate, primarily because of a lack of efficacy, inability to identify responders, and intolerable toxic effects [ 152, 153].

Existing knowledge of pharmacological effects and safety profiles of repurposed agents can expedite early phases of clinical development, shorten drug development timelines, and reduce failure rates due to pharmacokinetic and safety issues.

The history of weight-loss drug development is littered with failures, not least because most drug developers tend to fasten on to a single physiological goal--to reduce fat deposition, to improve insulin sensitivity, or to blunt appetite, for instance--and design a drug to influence that one contributor to obesity and its related ills.

Overall 75% of the costs of drug development is associated with failures mainly in the early stages of development (Goodall, 2004).

The assumption is that removing compounds with structural alerts from bioactivity screening libraries and short lists of drug candidates would reduce the risk of drug discovery and development failures.